December 1, 2016, 8:30-4:00 p.m.

The Open Data Science Symposium is open to the public and will be available through a webcast.

Big Data is an underutilized resource for innovation and discovery in biomedical research and the NIH is committed to unleashing its full potential by making it an open and easily accessible resource. The Open Data Science Symposium will feature discussions with the leaders in big data, open science, and biomedical research while also showcasing the finalists of the Open Data Science Prize, a worldwide competition to harness the innovative power of open data.

Please Register for the Open Data Science Symposium by November 18, 2016.

Access to cancer screening services in Nigeria, and identifying symptom changes in schizophrenia and depression patients are the focuses of the 2016 Research and Innovative Seed Grant award recipients, highlighting a collaborative research program between the University of Maryland, Baltimore (UMB)and the University of Maryland, College Park (UMCP). Part of the University of Maryland: MPowering the State initiative, the Seed Grant program was established to create opportunities for collaboration between disciplines and between the universities. All areas of research at UMB and UMCP are considered for funding.

By the end of next year, Harpoon Medical's minimally invasive surgical tool could be in operating rooms across Europe.

Harpoon still is testing the technology, but believes its device could revolutionize mitral valve repair, a hours-long surgery that requires splitting the breastbone and stopping the heart. Harpoon's tool can finish the job in a hour and a half through a small incision.

Washington-area companies raised nearly $300 million in venture capital funding during the third quarter, putting the region on track to reach $1 billion in investments by the end of the year, according to recently released data from the National Venture Capital Association.

In all, 49 local companies raised $299.5 million during the third quarter, a 47 percent increase from the $204 million the region’s firms secured during the same period last year, according to PitchBook, a research company that provided the data for the association’s report.

BioFactura, Inc. was granted patent rights by China’s State Intellectual Property Office (SIPO) protecting the core technologies of its proprietary StableFast™ Biomanufacturing Platform. SIPO allowed 17 claims broadly covering composition of matter and methods. StableFast™ is BioFactura’s proprietary NS0-based system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible. The Company is developing high-value biosimilars both internally and collaboratively.

For a while, Illumina—the 800-pound gorilla of genomics—could do no wrong. The DNA-sequencing company's market cap more than quadrupled from 2012, to peak at a whopping $34 billion, fueled in part by the growing hype around the potential of genomics to transform how we prevent, diagnose, and treat disease, as well as facilitate medical research discoveries.

Investigators at the Johns Hopkins University School of Medicine’s Brain Injury Outcomes program and the Institute for Clinical and Translational Research have been awarded a seven-year, $25 million grant from the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) to form, along with Tufts University School of Medicine, one of three Trial Innovation Centers.

Madison, Wisconsin-based Propeller Health has closed a $21.5 million Series C financing round, with new investors 3M Ventures, S.R. One, Limited and Hikma Ventures, plus existing investors Safeguard Scientifics and Social Capital. The funding will be used to further Propeller’s digitally-guided therapy platform.

Propeller’s aim is to simplify management of chronic respiratory diseases like asthma and COPD through sensors that attached to inhalers and sync to a companion app. The digitally-guided therapy platform is able to integrate with multiple sources, including connected medications, and uses machine learning to design a personalized therapy plan for each user.

Ever lose something and go crazy trying to find it, only to discover it was right in front of you all along?

A few days ago I attended back-to-back events. The first was a late afternoon party celebrating the 10th anniversary of a client, Printfresh Studio. Most of the women reading this have one of their designs in their closet. I met another attendee who suggested we get together to discuss mutual opportunities to refer our clients.   We traded business cards.

With the visionary language of large federal initiatives like the “Cancer Moonshot” or provocative branding such as “NIH…Turning Discovery into Health®” and the National Institute of Health website further touting “revolutionary ideas often come from unexpected directions,” one might assume an equally ambitious approach is being taken to ensure federal life sciences research is going toward research with the most promise for positive impact and scientific advancement.  One of the calls of Vice President Joe Biden’s recent Cancer Moonshot report was urging not to accept a “business as usual” approach. A recent report underscores why that may be a problem at the National Institutes of Health (NIH).

Personal Genome Diagnostics Inc. (PGDx), a leading provider of advanced cancer genome testing products and services, today announced that it has licensed rights to patent pending microsatellite instability (MSI) testing technology from Johns Hopkins University to help identify candidates for immune checkpoint inhibition. PGDx already includes the MSI technology in its pan cancer genomic tissue assays for patients and drug developers, and will be incorporating it into the recently launched PlasmaSELECT™ 64 non-invasive pan cancer assay. The company also includes the MSI technology in its PROGENEUS™ technology transfer enterprise solution, which enables advanced cancer genomic testing by local and regional laboratories that have next-generation sequencing (NGS) capabilities.

We recently released our inaugural PitchBook-NVCA Venture Monitor as a comprehensive resource on all matters venture capital. You can download the full 20-page report for free, but if you’d like to fast forward to the highlights, we’ve collated the top charts below:

Superbugs are causing a super problem in health care, but combating these drug-resistant bacteria presents quite a challenge. Many antibiotic prescriptions administered in the U.S. are either unnecessary or inappropriate and can lead to antibiotic-resistant infections or other adverse events. In an effort to improve antibiotic use, the Agency for Healthcare Research and Quality within the U.S. Department of Health and Human Services has awarded the Johns Hopkins Armstrong Institute for Patient Safety and Quality a $16 million contract, which will be spread over a period of five years — two initial years, plus three optional years. The Armstrong Institute will collaborate with the Chicago-based research institute NORC to identify which approaches are most helpful and to operationalize efforts to optimize antibiotic prescribing.

Two University of Maryland, Baltimore (UMB) researchers and a UM Venture startup company stemming from the University’s tech transfer efforts received financial awards to accelerate the commercial development of their biomedical inventions into treatments and devices to meet today’s health challenges.

 For the last eight years, the UMB Commercial Advisory Board and the Johns Hopkins Alliance for Science and Technology have held a yearly meeting of faculty of both universities, advisors and potential investors to explore pathways to commercializing inventions created in the universities’ laboratories, and encourage entrepreneurship among faculty members.  This year, $200,000 was awarded to faculty and startup companies from both universities. UMB inventors competed for a UM Ventures Award and one of two Abell Foundation Awards. UM Venture start-ups presented their companies for the chance to win a UM Venture Start-up Award.  This year’s UMB-affiliated awards went to:

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Amitiza (lubiprostone; Sucampo and Takeda) for the addition of two adverse reactions: syncope and hypotension.

Cases of syncope and hypotension have been reported with Amitiza in the postmarketing setting. Most cases have occurred in patients taking 24mcg twice daily and some occurred within an hour after taking the first dose or subsequent doses. The new label addition states that syncope and hypotension generally resolved following Amitiza discontinuation or prior to next dose, but recurrence has been reported with subsequent doses. Several cases reported concomitant use of medications known to lower blood pressure, which may increase the risk for the development of syncope or hypotension. Clinicians are advised to make patients aware of the risk; side effects such as diarrhea and vomiting may increase the risk for syncope and hypotension. 

As cybersecurity becomes more of an imperative for individuals and organizations, several regions in the US are investing money and efforts in security innovation.

Silicon Valley may be the most famous hotspot for tech innovation in the country, but it's far from the only place driving cybersecurity advancement. Areas such as the Washington, DC region and the Boston metro area are home to a growing number of security startups and incubators.

THE 7TH GALIEN FORUM EVENT: The 2016 Galien Forum will take place on the morning of October 27th, 2016, and will feature round table debates focusing on critical global healthcare issues and challenges. Our annual life science Forum is rapidly becoming a leading event for discussing issues of innovation in the industry. The Galien Forum brings together leading CEOs, biomedical experts from industry, academia and government.

Marriott International Inc. has selected downtown Bethesda as the site of its new headquarters. Exactly where is still to be determined.

The hospitality giant (NASDAQ: MAR), now the largest in the world following its merger with Starwood Hotels & Resorts Worldwide Inc., says it is still considering several Metro-accessible sites for a $600 million facility. It expects to make that selection in the first half of 2017.

On Jan. 20, 2015, about 30 minutes into his State of the Union Address, President Barack Obama said the words that would set in motion a health research initiative that could exceed the scope of any that has come before it.

Obama told listeners that he was green-lighting the launch of the Precision Medicine Initiative, a program two decades in the making that would begin where the groundbreaking Human Genome Project left off.

The Clark Charitable Foundation gifted Johns Hopkins University $15 million to provide financial aid and create a new academic program for undergraduate engineering students.

The gift honors the late A. James Clark, a former trustee of the university and of Johns Hopkins Medicine and former CEO of Clark Enterprises and Clark Construction Group LLC, one of the country’s largest privately held general building contractors. It is the largest endowed scholarship gift ever given to the university’s Whiting School of Engineering.

Today CosmosID announced participation in Vice President Biden's National Cancer Moonshot, which aims to accelerate progress in preventing, diagnosing, and treating cancer. CosmosID will provide access to its automated bioinformatics platform, MetaGenID, for five cancer microbiome research studies (valued at $150,000) to understand how the microbiome (i.e. oral, gut, and skin) contributes to development of specific cancers.

As part of the White House's Cancer Moonshot Initiative, today, SHARE For Cures (www.SHAREForCures.org) launched a technology platform and study aimed to gather a better understanding of the real-world use of novel cancer immunotherapy drugs.   

SHARE For Cures' new SHARE platform will easily and securely gather clinical, wellness, lifestyle, and patient-reported data about cancer immunotherapy use, side effects and benefits.  Once gathered, the data will enable researchers to better understand how these new therapies are being used outside of clinical trials, as well as the health impact of specific drugs on real-world patients. 

Vertex says it has updated an R&D collaboration with Cystic Fibrosis Foundation Therapeutics (CFFT) stretching back more than a decade.

Under the updated Research, Development and Commercialization Agreement, disclosed in a regulatory filing yesterday, CFFT—the Foundation’s nonprofit drug discovery and development affiliate—agreed to pay Vertex $75 million upfront, as well as up to $6 million annually toward development funding.

Facing federal and state pressure to raise retention and graduation rates, dozens of colleges and universities are developing analytics tools to help students make better decisions about everything from courses to social activities.

Purdue University has notified its 7,300 incoming freshman about a new web application that could help them better acclimate to life on campus. Administrators at the West Lafayette, Ind., school view the software as a critical tool for an institution whose graduation rate hovers at around 50 percent.

PricewaterhouseCoopers published its quarterly MoneyTree Report Friday showing that startups of all stripes garnered a total of $10.6 billion through 891 deals nationwide. However, the deal value and the number of deals fell 36 percent and 25 percent respectively from the same quarter last year.

Venture capitalists invested $19.6 million in Maryland companies in the third quarter, the lowest total in any quarter since 1997.

The total investment represents a 76 percent decrease from the second quarter and is down 86 percent from the third quarter last year, according to a MoneyTree Report from PricewaterhouseCoopers LLP and the National Venture Capital Association, based on data provided by Thomson Reuters.

MD Start, a European medical technology accelerator, announced Thursday that it has raised $11.5 million to create and fund four new French companies that can fulfill unmet needs in the medical device market.

The round was led by French Tech Acceleration Fund managed by Bpifrance, a French public investment bank. Other returning investors were French venture capital firm Sofinnova Partners, Dublin-based Medtronic, and LivaNova, a London-based medical device company.

An affiliate of Alexandria Real Estate Equities Inc. (NYSE: ARE), an urban office REIT based in Pasadena, Calif., has purchased Torrey Ridge Science Center in San Diego’s Torrey Pines submarket. Walton Street Capital and SteelWave sold the campus to Alexandria for $182.5 million.

Torrey Ridge Science Center is a Class A life science campus leased to companies such as Regulus Therapeutics, Pacira Pharmaceuticals, Nitto BioPharma, Interpreta and BP Technology Ventures. The three-building, 291,799-square-foot campus was 87 percent leased at the time of sale.

The Johns Hopkins University earned $58 million in licensing revenue in its 2016 fiscal year, three times more than in the prior year.

Johns Hopkins Technology Ventures, the university's commercialization office, attributed the spike in part to a major sublicensing deal between one of its portfolio companies, Immunomic Therapeutics, and Japanese pharmaceutical company Astellas Pharma.

The Washington DC/Baltimore Chapter of Women In Bio is presenting a program to learn about board service in the public and private sectors. If you are a budding entrepreneur looking to develop a board, this is the event for you. If you were recently named to a board and want to know more about your responsibilities, this is the event for you. If you want to start a business/nonprofit and need to know how to set up a board, this is the event for you.

Wed, Nov 16, 2016 at 6:00 PM 

Five Top Intellectual Property Legal Experts and a Room Filled with Life Science and Healthcare Entrepreneurs…what could possibly happen?

Strategies for Start-ups (and Non-Start-ups) to Maintain, Protect and Unlock their Intellectual Property

The workshop is intended for non-lawyers to understand IP issues and answer questions on just about every aspect of IP including; Copyrights, Trade Secrets, Trademarks, Patents, licensing, IP Due Diligence, IP Strategy, etc.

NATURE OF WORK

The Senior Grants and Contracts Manager will be tasked with the preparation, drafting, review and negotiation of contractual agreements with a special emphasis on agreements that support biomedical research initiatives and partnerships. S/he should have a strong customer service orientation and be able to identify process improvements so that transactions are completed with the right balance of efficiency and risk mitigation. S/he will report to the Director of Operations but will serve the contracting needs of colleagues across the Foundation. Strong writing, analytical and organizational skills must be matched with a sense of flexibility, entrepreneurial spirit and good cheer.

Technologists and entrepreneurs are reshaping cities like Baltimore with companies that bring new residents and products that change how we interact with the landscape. With a new mayor set to take office in Baltimore following the November 8 general election, it’s worth considering what the tech community wants to see at City Hall.

Ike Leggett says he will not seek a fourth term as Montgomery County executive.

Leggett, a former Howard University law professor who became the county’s first African American councilman and county executive, first announced publicly Sunday he would not run again at a fundraiser for an anti-term-limits group.

The Rockville biotech says two versions of its ADHD drug could serve a potential $7 billion market.